Evolution of the treatment of attention-deficit/hyperactivity disorder in children: A review

Clinical Therapeutics

Volumn 30, Issue 5, 2008, Pages 942-957

  Findling, Robert L ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

attention deficit hyperactivity disorder; children; lisdexamfetamine; nonstimulants; prodrugs; stimulants

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; LISDEXAMFETAMINE; METHYLPHENIDATE; PEMOLINE; PLACEBO; SPANSULE;

ABDOMINAL PAIN; ANOREXIA; ANXIETY; APPETITE; AREA UNDER THE CURVE; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CRYING; DEPRESSION; DRUG ABSORPTION; DRUG ABUSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMOTION; HABIT; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; MEDICAL LITERATURE; MEDLINE; MENTAL INSTABILITY; NAUSEA; ONYCHOPHAGIA; OPTIMAL DRUG DOSE; PARENT; PUBLICATION; RATING SCALE; SADNESS; SCHOOL HEALTH SERVICE; SIDE EFFECT; SOCIAL BEHAVIOR; SOMNOLENCE; SORE THROAT; STOMACH PAIN; SUSTAINED RELEASE FORMULATION; TEACHER; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; HUMANS; METHYLPHENIDATE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PRODRUGS; PROPYLAMINES;

EID: 44849117829     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.05.006     Document Type: Article

References (76)

1. Faraone S., Sergeant J., Gillberg C., and Biederman J. The worldwide prevalence of ADHD: Is it an American condition?. World Psychiatry 2 (2003) 104-113
2. American Psychiatric Association. Attention-deficit and disruptive behavior disorders. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision (2000), American Psychiatric Association, Washington, DC 885-893
3. Kessler R., Adler L., Barkley R., et al. The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey replication. Am J Psychiatry 163 (2006) 716-723
4. Williams J., Klinepeter K., Palmes G., et al. Diagnosis and treatment of behavioral health disorders in pediatric practice. Pediatrics 114 (2004) 601-606
5. Rappley M. Attention deficit-hyperactivity disorder. N Engl J Med 352 (2005) 165-173
6. Pliszka S., Crismon M., Hughes C., et al., for the Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-Deficit/Hyperactivity Disorder. The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45 (2006) 642-657
7. López F. ADHD: New pharmacological treatments on the horizon. J Dev Behav Pediatr 27 (2006) 410-416
8. Patrick K., Gonzalez M., Straughn A., and Markowitz J. New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder. [published correction appears in Expert Opin Drug Deliv . 2005;22:417]. Expert Opin Drug Deliv 2 (2005) 121-143
9. McGough J., Wigal S., Abikoff H., et al. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord 9 (2006) 476-485
10. Biederman J., Lopez F., Boellner S., and Chandler M. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 10 (2002) 258-266
11. Pliszka S., and for the AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children nd adolescents ith attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46 (2007) 894-921
12. Krishnan S., and Moncrief S. An evaluation of the cytochrome P450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos 35 (2007) 180-184
13. Biederman J., Krishnan S., Zhang Y., et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NNRP-104) in children with attention-deficit/hyperactivity disorder: A Phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 29 (2007) 450-463
14. Biederman J., Boellner S., Childress A., et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: A double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 62 (2007) 970-976
15. Focalin [package insert] (2001), Novartis Pharmaceuticals Corporation, East Hanover, NJ
16. Ritalin, Ritalin SR [package insert] (2004), Novartis Pharmaceuticals Corporation, East Hanover, NJ
17. Dexedrine, Dexedrine Spansule [package insert] (2006), GlaxoSmithKline, Research Triangle Park, NC
18. DextroStat [package insert] (2003), Shire US Inc, Newport, Ky
19. Adderall [package insert] (2005), Shire US Inc, Wayne, Pa
20. Focalin XR [package insert] (2005), Novartis Pharmaceuticals Corporation, East Hanover, NJ
21. Metadate ER [package insert] (2002), Celltech Pharmaceuticals Inc, Rochester, NY
22. Metadate CD [package insert] (2003), Celltech Pharmaceuticals Inc, Rochester, NY
23. Methylin ER [package insert] (2005), Mallinckrodt Inc, St. Louis, Mo
24. Ritalin LA [package insert] (2004), Novartis Pharmaceuticals Corporation, East Hanover, NJ
25. Concerta [package insert] (2004), McNeil-PPC Inc, Fort Washington, Pa
26. Daytrana [package insert] (2006), Shire US Inc, Wayne, Pa
27. Adderall XR [package insert] (2004), Shire US Inc, Newport, Ky
28. Strattera [package insert] (2005), Eli Lilly and Co, Indianapolis, Ind
29. Vyvanse [package insert] (2007), Shire US Inc, Wayne, Pa
30. Biederman J., Quinn D., Weiss M., et al. Efficacy and safety of Ritalin® LA, a new once daily, extended-release dosage form of methylpheni-date, in children with attention-deficit/hyperactivity disorder. Pediatr Drugs 5 (2003) 833-841
31. Findling R., Bukstein O., Melmed R., et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patien nts with attention-deficit/hyperactivity disorder. [published correction appears in J Clin Psychiatry. 2008;669:3329]. J Clin Psychiatry 69 (2008) 149-159
32. Greenhill L., Findling R., Swanson J., and for the ADHD Study Group. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 109 (2002) e39
33. Greenhill L., Muniz R., Ball R., et al. Efficacy and safety of dexmethyl-phenid date extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45 (2006) 817-823
34. Wolraich M., Greenhill L., Pelham W., et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 108 (2001) 883-892
35. Efron D., Jarman F., and Barker M. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity diso order: A double-blind, crossover trial. Pediatrics 100 (1997) e6-e13
36. Findling R., Short E., and Manos M. Developmental aspects of psychostimulant treatment in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 40 (2001) 1441-1447
37. Pelham Jr. W., Greenslade K., Vode-Hamilton M., et al. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: A comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 86 (1990) 226-237
38. Pliszka S., Browne R., Olvera R., and Wynne S. A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 39 (2000) 619-626
39. Kelsey D., Sumner C., Casat C., et al. Once-ddaily atomoxetine treatment for children with attention-deficit/hyperactivity diso order, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics 114 (2004) e1-e8
40. Michelson D., Faries D., Wernicke J., et al., for the Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 108 (2001) e83
41. Bradley C. The behavior of children receiving enzedrine. Am sychiatry 94 (1937) 577-585
42. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56 (1999) 1073-1086
43. American Academy of Pediatrics, Subcommittee on Attention-Deficit/Hyperactivity Disorder, Committee on Quality Im mprovement. Clinical practice guideline: Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 1108 (2001) 1033-1044
44. American Academy of Pediatrics, Committee on Quality Im mprovement, Subcommittee on Attention-Deficit/Hyperactivity Disorder. Clinical practice guideline: Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 1105 (2000) 1158-1170
45. Wolraich M., and Doffing M. Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity diso order with meth hylphenidate. CNS Drugs 118 (2004) 2243-2250
46. Kollins S., Rush C., Pazzaglia P., and Ali J. Comparison of acute behavioral effects of sustained-release and immediate-release methylpheni-date. Exp Clin Psychopharmacol 6 (1998) 367-374
47. Swanson J., Gupta S., Lam A., et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity diso order: Proof-of-concept and proof-of-pproduct studies. Arch Gen Psychiatry 60 (2003) 204-211
48. Swanson J., Gupta S., Guinta D., et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 66 (1999) 295-305
49. Pelham W., Gnagy E., and Burrows-Maclean. Once-a-day Concerta methylphenidate versus three-times-daily methylphenid in laboratory and natural settings. Pediatrics 107 (2001) e105-e119
50. Loney J., and Milich R. Hyperactivity, inattention, and aggression in clinical practice. In: Wolraich M., and Routh D. (Eds). Advances in Developmental and Behavioral Pediatrics 3 (1982), JAI Press, Greenwich, Conn 113-147
51. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Revised ed (1976), National Institute of Mental Health, Rockville, Md 218-222 DHEW publication no ADM 76-338
52. Conners C. Rating scales in attention-deficit/hyperactivity disorder: Use in assessment and treatment monitoring. J Clin Psychiatry 59 Suppl 7 (1998) 24-30
53. Wigal S., Gupta S., Guinta D., and Swanson J. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull 33 (1998) 47-53
54. Swanson J., Agler D., Fineberg E., et al. University of California, Irvine, laboratory school protocol for pharmacokinetic and pharmaco-dynamic studies. In: Greenhill L., and Osman B. (Eds). Ritalin: Theory and Practice. 2nd ed (2000), Mary Ann Liebert, New York, NY 405-430
55. DuPaul G., Power T., Anastopoulos A., and Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation (1998), Guilford Press, New York, NY
56. Conners C., Sitarenios G., Parker J., and Epstein J. The revised Conners' Parent Rating Scale (CCPRS-RR): Factor structure, reliability, and criterion validity. J Abnorm Child Psychol 26 (1998) 257-268
57. Keating G., and iggitt P. exmethyl-phenid date. Drugs 62 (2002) 1899-1904
58. McGough J., Pataki C., and Suddath R. Dexm meth hylp phenid date extended-release capsules for attention deficit hyperactivity disorder. Expert Rev Neurother 5 (2005) 437-441
59. Pelham W., Gnagy E., Chronis A., et al. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenid date in children with attention-deficit/hyperactivity disorder. Pediatrics 104 (1999) 1300-1311
60. Swanson J., Wigal S., Greenhill L., et al. Analog classroom assessment of Adderall in children with ADHD. J Am Acad Child Adolesc Psychiatry 37 (1998) 519-526
61. Goyette C., Conners C., and Ulrich R. Normative data on revised Conners parent and teacher rating scales. J Abnorm Child Psychol 6 (1978) 221-236
62. Faraone S., Biederman J., and Roe C. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: A metaanalysis. J Clin Psychopharmacol 22 (2002) 468-473
63. McGough J., Biederman J., Greenhill L., et al. Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall. J Am Acad Child Adolesc Psychiatry 42 (2003) 684-691
64. Brown G., Ebert M., Mikkelsen E., and Hunt R. Behavior and motor activity response in hyperactive children and plasma amphetamine levels follo ow wing a su ustained release preparation. J Am Acad Child Psychiatry 19 (1980) 225-239
65. Gibson A., Bettinger T., Patel N., and Crismon M. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother 40 (2006) 1134-1142
66. Spencer T., Biederman J., Wilens T., and Faraone S. Novel treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry 663 Suppl 12 (2002) 16-22
67. Wilens T., Spencer T., Biederman J., et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 158 (2001) 282-288
68. Heil S., Holmes H., Bickel W., et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 67 (2002) 149-156
69. Albert A. Chemical aspects of selective toxicity. Nature 1182 (1958) 421-422
70. Stanczak A., and Ferra A. Prodrugs and soft drugs. Pharmacol Rep 58 (2006) 599-613
71. Schuster C. History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs. Drug Alcohol Depend 83 Suppl 1 (2006) S8-S14
72. Shojaei A, Ermer JC, Krishnan S. Lisdexamfetamine dimesylate as a treatment for ADHD: Dosage formulation and pH effects.Poster presented at: Annual meeting of the American Psychiatric Association; May 19-24, 2007; San Diego, Calif.
73. Ermer JC, Shojaei AH, Biederman J, Krishnan S. Improved interpatient pharmacokinetic variability of lisdexamfetam mine dimesylate compared with mixed amphetamine salts extended release in children aged 6 to 12 years with attention-deficit/hyperactivity disorder. Poster presented at: Annual meeting of the American Psychiatric Association; May 19-24, 2007; San Diego, Calif.
74. Jasinski D, Krishnan S. Abuse liability of intravenous lisdexamfetamine dimesylate (LDX; NRP104). Poster presented at: US Psychiatric & Mental Health Congress; November 16-19, 2006; New Orleans, La.
75. Jasinski D., and Henningfield J. Human abuse liability assessment by measurement of subjective and physiologic cal effects. NIDA Res Monogr 92 (1989) 73-100
76. Jasinski D, Krishnan S. A double-blind, randomized, placeb bo- and active-controlled,6-period cross-?May 2008 957 R.L. Findling over study to evaluate the likability, safety, and abuse potential of lisdexamfetamine dimesylate (LLDX) in adult stimulant abusers. Poster presented at: US Psychiatric & Mental Health Congress; November 16-19, 2006; New Orleans, La.